Business
Dundee University Collaboration
Dundee University Collaboration.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 7992X Physiomics PLC 16 January 2014 \n \n\nPhysiomics plc\n(\"Physiomics\") or (\"the Company\")\n \nPhysiomics to collaborate with the University of Dundee to \"optimize drug design and testing\" with grant support from the Northern Research Partnership \n \n \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a collaboration agreement with the University of Dundee. Physiomics part of the collaboration will be fully funded by the Northern Research Partnership (\"NRP\") in the form of an \"Early Career Researcher Engagement and Exchanges with Business & Industry\" agreement.\n \nUnder the collaboration agreement, we will collaborate directly with Dr Raluca Eftimie and Dr Fordyce A. Davison to assist them in analysing clinical data with an emphasis on developing new mathematical approaches for drug development. The research project will commence in January 2014. \n \n \nDr Mark Chadwick, CEO of Physiomics, commented:\n\"We are pleased to collaborate with such a well know institution in biological modelling. We anticipate that this will further improve our clinical modelling capabilities.\"\n \n \nEnquiries:\n \nPhysiomics plc \nDr Mark Chadwick, CEO\n+44 (0)1865 784 980\n \n \nWH Ireland Limited (broker/nomad)\nKaty Mitchell\n+44 (0) 161 832 2174\n \n \n \nAbout Physiomics plc\n \nPhysiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.\n \nPhysiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical researc...